MacroGenics

Yahoo Finance • 16 days ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 16 days ago

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Neuroblastoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The neuroblastoma market has witnessed significant growth, projected to expand from $3.14 billion... Full story

Yahoo Finance • last month

Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant

[FDA headquarters in Washington DC.] JHVEPhoto The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY [https://seekingalpha.com/symbol/INCY]) and MacroG... Full story

Yahoo Finance • 2 months ago

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s m... Full story

Yahoo Finance • 2 months ago

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that... Full story

Yahoo Finance • 5 months ago

After-Hours Gainers: MGNX, SLS, KRMD, HYPR, WVE Post Sharp Moves Following Q3 Updates

(RTTNews) - Several small-cap healthcare and biotech names posted notable price increases in after-hours trading on Wednesday, following earnings updates or ahead of scheduled financial disclosures. MacroGenics, Inc. (MGNX) rose 10.2% to... Full story

Yahoo Finance • 5 months ago

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending devel... Full story

Yahoo Finance • 5 months ago

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, Pr... Full story

Yahoo Finance • 6 months ago

3 Promising Penny Stocks With Market Caps Over $100M

Major stock indexes in the United States recently ended a mixed session, with the Dow Jones Industrial Average closing at a record high amid a flurry of corporate earnings reports. For investors seeking opportunities beyond the blue-chip s... Full story

Yahoo Finance • 7 months ago

What's going on in today's after hours session

The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT SPRC [https://www.chartmill.co... Full story

Yahoo Finance • 7 months ago

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ P... Full story

Yahoo Finance • 8 months ago

Thursday's after hours session: top gainers and losers

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] GAINERS TICKER CHANGE COMMENT MODV [https://www.chartmill.com/stock/quote/MODV/... Full story

Yahoo Finance • 8 months ago

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents... Full story

Yahoo Finance • 8 months ago

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective a... Full story

Yahoo Finance • 8 months ago

STNG Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of Scorpio Tankers Inc (Symbol: STNG) crossed above their 200 day moving average of $45.95, changing hands as high as $47.89 per share. Scorpio Tankers Inc shares are currently trading up about 2.7% on the... Full story

Yahoo Finance • 10 months ago

MacroGenics' SWOT analysis: biotech firm's stock faces pivotal year ahead

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics, finds itself at a critical juncture as it navigates through a challenging biotech landscape. Acc... Full story

Yahoo Finance • 10 months ago

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment... Full story

Yahoo Finance • 11 months ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC,... Full story

Yahoo Finance • 11 months ago

MacroGenics Announces Date of First Quarter 2025 Financial Results

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of... Full story

Yahoo Finance • last year

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase... Full story